A review of 62 Mayo Clinic patients who underwent cryoablation to treat cancerous kidney tumors shows that the patients are cancer free for up to two and a half years after having had the procedure. A ...

Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense (R) ...

Results were reported at a mean follow-up period of 36 months for 111 patients with 117 lesions. A summary of the key results were: In 91 patients (approximately 82%), no tumor recurrence was observed ...

Researchers report that freezing kidney tumors through percutaneous cryoablation shows promise for patients who are not good candidates for surgery. Mayo Clinic researchers report that freezing kidney ...

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the clearance of a cryoablation technology platform for the treatment of cancerous and benign ...

Icecure Medical ( ($ICCM) ) just unveiled an update. On December 10, 2025, IceCure Medical announced that its ProSense® Cryoablation technology ...

For patients with early-stage renal cell carcinomas (RCCs) that measure between 3 and 4 centimeters, a procedure that destroys the cancer by freezing – called cryoablation – yields a lower-risk of ...

IceCure Medical ICCM recently announced that the company had submitted final data to the FDA requesting market authorization for its ProSense System. ProSense is designed to provide cryoablation, an ...

CAESAREA, Israel, Dec. 5, 2024 /PRNewswire/ -- IceCure Medical Ltd. (ICCM) (NASDAQ: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that ...